Prothena Corp (PRTA) PT Lowered to $31 at BofA Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Prothena Corp (PRTA) PT Lowered to $31 at BofA Securities
September 30, 2024 1:03 PM EDT
RBC Capital analyst Kennen MacKay reiterated a Sector Perform rating and $24.00 price target on Prothena Corp (NASDAQ: PRTA).
The analyst said: "Shares of PRTA are down ~20% today, likely on the announcement of the departure of their CMO late last Friday... More
September 27, 2024 4:05 PM EDT
Prothena Corporation plc (NASDAQ: PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that Chad Swanson, Ph.D., has been appointed Chief Development Officer and will assume leadership of clinical development and medical functions. Chad will join Prothenas executive leadership team and will report to Gene Kinney, Ph.D., President and Chief Executive Officer. Hideki Garren, M.D., Ph.D., will pursue an opportunity at a large pharmaceutical company to lead a global product development division. Prothena will initiate a search for... More
